



Precision Medicine on Hypertension and Cardiovascular Diseases

Guest Editor:

Dr. Egidio Imbalzano
Department of Clinical and
Experimental Medicine,
University of Messina, 98122
Messina, Italy

Deadline for manuscript
submissions:


10 May 2024

Message from the Guest Editor

The personalization of pharmacological therapy for patients with cardiovascular disease represents one of the most interesting challenges of modern cardiology. Precision medicine intends to focus on relevant topics of daily clinical practice such as arterial hypertension, diabetes, heart failure, hypercholesterolemia, and atherosclerotic cardiovascular disease (ASCVD). In the field of therapy optimization and personalization, scientific research has introduced interesting innovations, and many others are underway (for example, SGLT2, PCSK9i, siRNA, antisense oligonucleotide).

These novel therapies have the potential to enhance drug delivery, reduce off-target effects, and provide prolonged therapeutic effects, improving patient outcomes. By targeting the root causes of cardiovascular diseases at the molecular level, these innovative therapies offer the hope for improving patient outcomes and reducing the global burden of cardiovascular morbidity and mortality. In this Special Issue, we welcome your submission of reviews, communications, and original research articles targeting any of these topics.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Senior Vice President and Director, Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Professor of Medicine Chief, Section of Hematologic Malignancies, Associate Director for Clinical Research, Division of Hematologic Malignancies and Cellular Therapy Duke Cancer Institute, Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[@JPM_MDPI](https://twitter.com/JPM_MDPI)